Journal article
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer
T John, H Akamatsu, A Delmonte, WC Su, JS Lee, GC Chang, X Huang, S Jenkins, YL Wu
Lung Cancer | Published : 2018
Abstract
Objectives: In AURA3 (NCT02151981), osimertinib treatment provided significant clinical benefit compared with platinum-pemetrexed in patients with epidermal growth factor receptor (EGFR) T790M-positive advanced non-small-cell lung cancer (NSCLC), whose tumors had progressed on previous EGFR-tyrosine kinase inhibitor therapy. This retrospective analysis investigated detection rates for T790M, common (exon 19 deletion and L858R), and rare EGFR mutations in tissue samples from the screened population of AURA3. Materials and methods: In AURA3, eligible patients were randomized 2:1 to receive oral osimertinib 80 mg once daily or intravenous platinum-pemetrexed every 3 weeks for up to six cycles. ..
View full abstractGrants
Funding Acknowledgements
The AURA3 study (NCT02151981) was supported by AstraZeneca, Cambridge, UK, the manufacturer of osimertinib. The study sponsor contributed to the design of the study, was involved in the collection, analysis and interpretation of data, in the writing of the manuscript, and in the decision to submit the manuscript for publication.